Bioniche Pharma launches generic antiarrhythmic agent

Justine Varieur Cadet | | Cardiovascular Business | Heart Rhythm
Bioniche Pharma, a developer of injectable pharmaceuticals, has launched ibutilide fumarate injection, the generic equivalent of Pfizer's antiarrhythmic drug Corvert .

Bioniche of Lake Forest, Ill., said it will supply ibutilide fumarate injection in 0.1 mg/mL, 10 mL vials.

The product has a boxed warning relating to proarrhythmic effects including potentially fatal arrhythmias (e.g., polymorphic ventricular tachycardia) and consideration for use in patients with chronic atrial fibrillation.

Justine Varieur Cadet

Related Content

FDA approves new short-term treatment for AFib, atrial flutter in critical care settings
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Eko Health’s AI platform for digital stethoscopes granted new CPT code
Predicting sudden cardiac death after a heart attack may be impossible—for now
Concomitant ablation surgery during heart operations boosts long-term survival
Johnson & Johnson MedTech gains FDA approval for Varipulse PFA system

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."